ArticleDiscover oncology2025
Causal relationship between gut microbiota and hepatocellular carcinoma: a two-sample Mendelian randomization and case-control study.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Gut Microbiota in Hepatocellular Carcinoma: Etiology-Specific Evidence, Mechanisms, and Translational Challenges.Journal of hepatocellular carcinoma · 2026Review
- Mendelian randomization analysis of immune cell populations, serum metabolites and hepatocellular carcinoma risk.Discover oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundAccumulating evidence from both observational studies and clinical trials has established a connection between the gut microbiome and hepatocellular carcinoma (HCC). Nevertheless, the causal relationship between gut microbes and hepatocellular carcinoma remains ambiguous.
methodsThe principal study method employed was Mendelian randomization (MR). The exposure group included 7738 samples from the MiBioGen Consortium Gut Microbiota Genome-Wide Association Study (GWAS), whereas the outcome group included 8,885,115 single nucleotide polymorphisms (SNPs) from the IEU OpenGWAS project database of hepatocellular carcinoma (HCC). Utilizing the MR-Egger regression, weighted median (WME), and weighted mode (WM) as supplemental methods for inverse variance weighting (IVW), the main basis was IVW. Additional sensitivity, pleiotropy, and heterogeneity tests were performed. To confirm the MR results, sequencing data from a case-control study were used. We enrolled 29 patients with HBV-HCC who were hospitalized at Tianjin Second People's Hospital between October 2022 and August 2023, and chose 21 healthy employees as controls.
resultsIVW analysis showed that gut Clostridia (OR = 0.554, 95%CI: 0.361-0.850, p = 0.007), Clostridiales (OR = 0.554, 95%CI: 0.361-0.850, p = 0.007), and Dorea (OR = 0.679, 95%CI: 0.479-0.964, p = 0.030) were protective factors against HCC. Gut Desulfovibrio piger (OR = 1.304, 95%CI: 1.080-1.499, p = 0.004), Bacteroides ovatus (OR = 1.304, 95%CI: 1.046-1.626, p = 0.018), Bacteroides stercoris (OR = 1.714, 95%CI: 1.183-2.483, p = 0.004), and Paraprevotella xylaniphila (OR = 1.256, 95%CI: 1.003-1.573, p = 0.047) were risk factors for HCC. A case-control study demonstrated that the relative abundances of gut Clostridia, Clostridiales, and Dorea were significantly higher in healthy controls than in patients with HCC. Conversely, the relative abundance of Bacteroides stercoris was lower in healthy controls than in patients with HCC.
conclusionThis study showed that gut Clostridia, Clostridiales, and Dorea were associated with a reduced risk of HCC, whereas gut Bacteroides stercoris was the exact opposite.
conclusionThis study demonstrated that gut Clostridia, Clostridiales, and Dorea were linked to a decreased HCC risk, while gut Bacteroides stercoris was linked to an increased HCC risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.